Only the cohort receiving 400 mg twice daily met the predefined criteria for success, showing better percentages in all primary endpoints, which were as follows: radiological objective response, a 50% decrease in PSA from baseline and the conversion of circulating tumor cell count. This evidence concerns the gene PROS1 and neoplasm.